FY2030 Earnings Forecast for Evotec Issued By HC Wainwright

Evotec AG (NASDAQ:EVO) – Stock analysts at HC Wainwright issued their FY2030 EPS estimates for Evotec in a report released on Wednesday, April 15th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of $0.48 for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.41) per share.

Evotec (NASDAQ:EVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 EPS for the quarter. The firm had revenue of $297.02 million for the quarter. Evotec had a negative net margin of 13.13% and a negative return on equity of 12.40%.

Several other brokerages also recently commented on EVO. Berenberg Bank assumed coverage on shares of Evotec in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Evotec has an average rating of “Hold” and a consensus price target of $7.00.

Evotec Price Performance

Shares of EVO stock opened at $3.26 on Friday. Evotec has a one year low of $2.31 and a one year high of $4.80. The company’s fifty day moving average price is $2.93 and its 200-day moving average price is $3.28. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.99 and a current ratio of 2.07.

Institutional Trading of Evotec

A number of institutional investors and hedge funds have recently bought and sold shares of EVO. Bank of America Corp DE increased its holdings in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after acquiring an additional 9,289 shares during the last quarter. XTX Topco Ltd bought a new stake in Evotec in the 2nd quarter valued at $66,000. Marshall Wace LLP bought a new stake in Evotec in the 2nd quarter valued at $169,000. BNP Paribas Financial Markets increased its holdings in Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares during the last quarter. Finally, Snowden Capital Advisors LLC bought a new stake in Evotec in the 2nd quarter valued at $122,000. 5.81% of the stock is currently owned by institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.